Trial Profile
A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Sepetaprost (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Acronyms Angel Study
- Sponsors Santen Inc
- 01 Apr 2022 Results published in the Journal of Ocular Pharmacology and Therapeutics
- 22 Jan 2020 Status changed from recruiting to completed.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.